Carl Zeiss Meditec AGXSWX:AFX 80 EBIT per Share is CHF2.11 as of Dec. 2025. GuruFocus rates XSWX:AFX with a GF Score™ of 80/100 and a GF Value™ of CHF69.46 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 690 Medical Devices & Instruments companies, Carl Zeiss Meditec AG ranks worse than 81.01% on this metric.
Carl Zeiss Meditec AG's EBIT per Share for the
three
months ended in Dec. 2025 was CHF0.02.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was CHF2.11.
During the past 12 months, the average EBIT per Share Growth Rate of Carl Zeiss Meditec AG was 11.30% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -16.80% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -2.30% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 6.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Carl Zeiss Meditec AG's EBIT per Share or its related term are showing as below:
XSWX:AFX'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -50.8 Med: 9.65 Max: 25.2
Current: -16.8
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Carl Zeiss Meditec AG was 25.20% per year. The lowest was -50.80% per year. And the median was 9.65% per year.
XSWX:AFX's 3-Year EBIT Growth Rate is ranked worse than 81.01% of 690
companies
in the Medical Devices & Instruments industry
Industry Median: 9.6
vs XSWX:AFX: -16.80
Carl Zeiss Meditec AG (XSWX:AFX) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Carl Zeiss Meditec AG EBIT per Share Related Terms
Carl Zeiss Meditec AG EBIT per Share Historical Data
* Premium members only.
The historical data trend for Carl Zeiss Meditec AG's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF2.11
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Carl Zeiss Meditec AG (XSWX:AFX) has a EBIT per Share of CHF2.11 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Carl Zeiss Meditec AG and its competitors. According to the industry distribution chart, Carl Zeiss Meditec AG ranks #559 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 81%.
Is Carl Zeiss Meditec AG's EBIT per Share too high?
Carl Zeiss Meditec AG's current EBIT per Share is CHF2.11. Based on the distribution chart, Carl Zeiss Meditec AG ranks #559 out of 690 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Carl Zeiss Meditec AG has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's EBIT per Share compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Carl Zeiss Meditec AG ranks #559 out of 690 companies for EBIT per Share. This places Carl Zeiss Meditec AG in the lower half of its industry. The industry median EBIT per Share is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.60, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Carl Zeiss Meditec AG and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carl Zeiss Meditec AG's current EBIT per Share is CHF2.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG (XSWX:AFX) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF69.46, compared to a current price of CHF25.10 — trading 63.9% below its estimated fair value. The current EBIT per Share is CHF2.11. Carl Zeiss Meditec AG's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Carl Zeiss Meditec AG (XSWX:AFX), the current EBIT per Share is CHF2.11 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carl Zeiss Meditec AG (XSWX:AFX) Overvalued in 2026?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued.
The current stock price of CHF25.10 is trading 63.9% below its estimated GF Value™ of CHF69.46.
GuruFocus considers Carl Zeiss Meditec AG to be Significantly Undervalued.
Key valuation signals for XSWX:AFX:
EBIT per Share: CHF2.11
GF Value™: CHF69.46 vs. price of CHF25.10 (63.9% below fair value)
No single metric tells the full story. See the XSWX:AFX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
80GF Score
Get the complete analysis for XSWX:AFX
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:AFX has been successfully added to your 
